StockData
OnKure Therapeutics, Inc. logo

OnKure Therapeutics, Inc. (OKUR) stock

OKURNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/30
$2.58−0.17 (-6.18%)

Close on Nov 17, 2026Market cap $104.48MP/E –Yield –

OnKure Therapeutics cash

Cash and short-term investments held at the end of each period.

OnKure Therapeutics's cash was $176.40M at Jun 30, 2026. For fiscal 2025 it was $59.05M, down 46.7% from the year before. The highest annual figure on record is $147.67M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$59.05M-46.7%
FY2024Dec 31, 2024$110.76M+5.3%
FY2023Dec 31, 2023$105.21M+13.4%
FY2022Dec 31, 2022$92.79M-37.2%
FY2021Dec 31, 2021$147.67M+175.4%
FY2020Dec 31, 2020$53.61M+206.3%
FY2019Dec 31, 2019$17.50M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$176.40M+111.6%
Q1 FY2026Mar 31, 2026$192.11M+98.7%
Q4 FY2025Dec 31, 2025$59.05M-46.7%
Q3 FY2025Sep 30, 2025$70.33M-8.3%
Q2 FY2025Jun 30, 2025$83.37M+40.5%
Q1 FY2025Mar 31, 2025$96.66M+18.3%
Q4 FY2024Dec 31, 2024$110.76M+5.3%
Q3 FY2024Sep 30, 2024$76.70M-38.9%
Q2 FY2024Jun 30, 2024$59.34M-58.4%
Q1 FY2024Mar 31, 2024$81.71M-12.9%
Q4 FY2023Dec 31, 2023$105.21M+13.4%
Q3 FY2023Sep 30, 2023$125.61M+8.2%
Q2 FY2023Jun 30, 2023$142.68M+12.5%
Q1 FY2023Mar 31, 2023$93.79M-32.4%
Q4 FY2022Dec 31, 2022$92.79M-37.2%
Q3 FY2022Sep 30, 2022$116.08M-26.4%
Q2 FY2022Jun 30, 2022$126.85M-24.2%
Q1 FY2022Mar 31, 2022$138.66M+52.0%
Q4 FY2021Dec 31, 2021$147.67M+175.4%
Q3 FY2021Sep 30, 2021$157.73M+1231.7%
Q2 FY2021Jun 30, 2021$167.33M+923.9%
Q1 FY2021Mar 31, 2021$91.22M+399.0%
Q4 FY2020Dec 31, 2020$53.61M+206.3%
Q3 FY2020Sep 30, 2020$11.85M–
Q2 FY2020Jun 30, 2020$16.34M–
Q1 FY2020Mar 31, 2020$18.28M–
Q4 FY2019Dec 31, 2019$17.50M–

More OnKure Therapeutics figures

See a number that looks wrong?